Request Demo
Last update 06 Dec 2025
Adalimumab Biosimilar (North China Pharma)
Last update 06 Dec 2025
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms Recombinant human monoclonal antibody specific for human tumor necrosis factor(North China Pharma), 重组人源抗人肿瘤坏死因子 (TNF-α)单克隆抗体 (华北制药) |
Target |
Action inhibitors |
Mechanism TNF-α inhibitors(Tumor necrosis factor α inhibitors) |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 26792L
Source: *****
Sequence Code 88699H
Source: *****
Related
1
Clinical Trials associated with Adalimumab Biosimilar (North China Pharma)CTR20200020
抗人肿瘤坏死因子单克隆抗体注射液I期临床试验
[Translation] Phase I clinical trial of anti-human tumor necrosis factor monoclonal antibody injection
100 Clinical Results associated with Adalimumab Biosimilar (North China Pharma)
Login to view more data
100 Translational Medicine associated with Adalimumab Biosimilar (North China Pharma)
Login to view more data
100 Patents (Medical) associated with Adalimumab Biosimilar (North China Pharma)
Login to view more data
100 Deals associated with Adalimumab Biosimilar (North China Pharma)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Ankylosing Spondylitis | Phase 1 | China | 06 Jul 2020 | |
| Ankylosing Spondylitis | Phase 1 | China | 06 Jul 2020 | |
| Psoriasis | Phase 1 | China | 06 Jul 2020 | |
| Psoriasis | Phase 1 | China | 06 Jul 2020 | |
| Rheumatoid Arthritis | Phase 1 | China | 06 Jul 2020 | |
| Rheumatoid Arthritis | Phase 1 | China | 06 Jul 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free